Insider Selling: KALA BIO, Inc. (NASDAQ:KALA) CFO Sells $13,016.78 in Stock

KALA BIO, Inc. (NASDAQ:KALA) CFO Mary Reumuth sold 1,706 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $7.63, for a total value of $13,016.78. Following the completion of the sale, the chief financial officer now directly owns 68,581 shares in the company, valued at approximately $523,273.03. This trade represents a 2.43 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

KALA BIO Price Performance

Shares of NASDAQ:KALA opened at $6.82 on Friday. The firm’s 50 day moving average is $6.70 and its two-hundred day moving average is $6.33. The firm has a market capitalization of $31.44 million, a P/E ratio of -0.55 and a beta of -2.11. The company has a current ratio of 2.15, a quick ratio of 2.15 and a debt-to-equity ratio of 3.18. KALA BIO, Inc. has a 52 week low of $4.21 and a 52 week high of $9.25.

KALA BIO (NASDAQ:KALA) last posted its earnings results on Tuesday, November 12th. The company reported ($1.93) EPS for the quarter, beating the consensus estimate of ($2.43) by $0.50. Analysts anticipate that KALA BIO, Inc. will post -10.84 earnings per share for the current year.

Institutional Investors Weigh In On KALA BIO

An institutional investor recently bought a new position in KALA BIO stock. SR One Capital Management LP bought a new stake in shares of KALA BIO, Inc. (NASDAQ:KALA) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO accounts for approximately 1.0% of SR One Capital Management LP’s holdings, making the stock its 9th largest position. SR One Capital Management LP owned approximately 15.76% of KALA BIO as of its most recent SEC filing. 24.61% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of KALA BIO in a research note on Friday, November 15th.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.